Balaxi Pharmaceuticals Ltd. (NSE: BALAXI), a branded IPR-driven pharmaceutical player with a growing footprint in frontier markets, announced its audited financial results for the quarter and year ended March 31, 2025, demonstrating strong operational execution and strategic progress.
Consolidated Revenue grew by 21% YoY, driven by solid performance across Africa and Latin America.Profitability remained resilient despite inflationary pressures, with healthy gross margins reflecting strong portfolio pricing power. 85 new product registrations were secured, bringing the total portfolio to 915 registrations across 7 countries. Expansion into new sales channels, including institutional (hospital) and tender-based businesses, unlocked new growth levers. Pharma formulation manufacturing facility in Hyderabad nears completion; commissioning and validation expected by Q1 FY26.
Speaking on the results, the management further added, “FY25 has been a pivotal year in Balaxi Pharmaceutical’s growth journey. The Company delivered a strong recovery, marked by solid execution, and a strategic pivot in our go-to-market approach. By targeting newer sales channels — including institutional (hospital) and tender business — and deepening our presence across key geographies, we successfully unlocked new growth levers.
Our consolidated revenue registered a healthy 21% growth, underpinned by satisfactory performance in both Africa and Latin America. In Africa, we sustained our leadership in branded generics, supported by strong distribution network and deep customer engagement. In Latin America, performance was equally encouraging, demonstrating our ability to scale rapidly in new markets through focused execution and differentiated product offerings. Despite inflationary pressure and higher administrative and employee related costs, our Profitability remained resilient. Gross profit margins continued to be healthy, reflecting the strength of our portfolio and pricing power in underserved markets.
During the year, we secured 85 new product registrations bringing our total portfolio to 915 products across seven countries in Africa and Latin America. This diversified and expanding product portfolio positions us to capture a significant increase in market share across our focus countries.
We also made substantial progress on the capex front. The construction and installation at Company’s first pharmaceutical formulation plant in Jadcherla, Hyderabad is now complete. Operational Qualification (0Q) and Validations are underway and expected to be concluded by end of June 2025. This backward integration will allow us to enhance our control on quality, ensure cost efficiency, and support our medium-to-long term growth ambitions.
Looking ahead, we remain focused on – Operationalising our first formulation facility in FY26; Expanding our branded formulations in existing and new markets; Investing in regulatory filings and pipeline development to enter higher-value markets; Continue to strengthen internal systems and supply chain resilience. We thank our all stakeholders — investors, employees, partners and customers — for their continued trust and support.
Balaxi Pharmaceuticals Ltd is a branded IPR-based pharmaceutical player focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. The Company is engaged in supplying branded and generic medicines through its well-built on ground infrastructure across Angola, Guatemala and Dominican Republic. These products are procured from WHO GMP certified contract manufacturers based in India, China and Portugal